company background image
SOPH

SOPHiA GENETICS NasdaqGS:SOPH Stock Report

Last Price

US$2.85

Market Cap

US$182.8m

7D

-5.3%

1Y

-82.1%

Updated

28 Sep, 2022

Data

Company Financials +
SOPH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SOPH Stock Overview

SOPHiA GENETICS SA operates as a healthcare technology company.

SOPHiA GENETICS SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SOPHiA GENETICS
Historical stock prices
Current Share PriceUS$2.85
52 Week HighUS$19.19
52 Week LowUS$2.16
Beta0
1 Month Change-19.26%
3 Month Change-21.27%
1 Year Change-82.08%
3 Year Changen/a
5 Year Changen/a
Change since IPO-82.99%

Recent News & Updates

Sep 21

SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies

SOPHiA GENETICS (NASDAQ:SOPH) has entered a partnership with precision oncology company Boundless Bio to develop therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers. Boundless Bio is developing the first ecDNA-directed therapies (ecDTx) as well as a precision diagnostic method called ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from a patient's tumor sequencing data. SOPHiA (SOPH) said its ability to harmonize data derived from diverse genomic instruments combined with Boundless Bio's drug development capabilities can optimize patient selection and clinical trial design and support a network of hospitals and academic centers to deliver new treatment options for oncogene amplified cancers. SOPHiA (SOPH) also recently entered into an agreement with Memorial Sloan Kettering Cancer Center to allow its global network of healthcare providers access to MSK's proprietary tumor sequencing tests. Seeking Alpha's Quant Rating views SOPHiA (SOPH) as a hold with high marks for growth and valuation.

Aug 09

SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M

SOPHiA Genetics press release (NASDAQ:SOPH): Q2 GAAP EPS of -$0.39 in-line. Revenue of $11.7M (+15.0% Y/Y) misses by $0.25M.

Jul 01
We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely

We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

SOPHUS Healthcare ServicesUS Market
7D-5.3%-0.9%-2.0%
1Y-82.1%-52.4%-20.3%

Return vs Industry: SOPH underperformed the US Healthcare Services industry which returned -53.8% over the past year.

Return vs Market: SOPH underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is SOPH's price volatile compared to industry and market?
SOPH volatility
SOPH Average Weekly Movement13.0%
Healthcare Services Industry Average Movement10.3%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: SOPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: SOPH's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011518Jurgi Camblonghttps://www.sophiagenetics.com

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide.

SOPHiA GENETICS SA Fundamentals Summary

How do SOPHiA GENETICS's earnings and revenue compare to its market cap?
SOPH fundamental statistics
Market CapUS$182.84m
Earnings (TTM)-US$92.78m
Revenue (TTM)US$43.82m

4.2x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SOPH income statement (TTM)
RevenueUS$43.82m
Cost of RevenueUS$16.12m
Gross ProfitUS$27.71m
Other ExpensesUS$120.49m
Earnings-US$92.78m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.45
Gross Margin63.22%
Net Profit Margin-211.72%
Debt/Equity Ratio0%

How did SOPH perform over the long term?

See historical performance and comparison